Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8356 to 8370 of 8886 results

  1. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  2. Surgical site infections: prevention and treatment - Update

    Discontinued Reference number: GID-NG10374

    NICE guideline
    Discontinued

  3. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued Reference number: GID-TA11171

    Technology appraisal guidance
    Discontinued

  4. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  5. Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1140).

    Withdrawn guidance

  6. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [ID6738]

    In development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [ID6739]

    In development Reference number: GID-TA11880 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  10. Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]

    In development Reference number: GID-TA10404 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    Discontinued Reference number: GID-HST10020

    Highly specialised technologies guidance
    Discontinued

  12. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Discontinued Reference number: GID-HST10022

    Highly specialised technologies guidance
    Discontinued

  13. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    Discontinued Reference number: GID-TA11074

    Technology appraisal guidance
    Discontinued

  14. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    In development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

    Technology appraisal guidance
    Discontinued